Exploration of histone protein γ‐<scp>H2AX</scp> as a prognostic factor in soft tissue sarcomas and its association with biological behavior, immune cell environment and survival in leiomyosarcoma
This study evaluates the H2AX/γ-H2AX expression in soft tissue sarcomas (STS), its implications for biological behavior and immune environment, and its potential as a prognostic biomarker. RNA-Seq data from 237 STS were obtained from The Cancer Genome Atlas project. Patients were stratified by H2AX mRNA expression using a survival-associated cutoff. Differentially expressed genes and pathways as well as immune signatures between H2AX<sup>high</sup>- and H2AX<sup>low</sup> tumors were identified with DESeq2 analysis, gene set enrichment analyses (GSEA), Enrichr pathway analysis and CIBERSORTx. Tissue microarrays of a different cohort of 291 STS were generated for immunohistochemical staining to assess γ-H2AX protein expression, followed by statistical evaluation. High H2AX mRNA expression was associated with shorter overall survival (OS) in STS (p = 0.02), particularly in leiomyosarcomas (LMS) (p < 0.001), and was a negative prognostic factor in LMS (HR 11.15, p < 0.001). H2AX<sup>high</sup> LMS tumors showed upregulation of cell cycle-related pathways, while H2AX<sup>low</sup> LMS exhibited increased inflammatory activity, including elevated M1 macrophage signatures and resting mast cell signatures (both p < 0.001). High γ-H2AX protein levels were an independent negative prognostic factor in the total LMS cohort (HR 12.12, p = 0.025) and in the subgroup of non-uterine LMS (HR 153.80, p = 0.013). Consistent with CIBERSORTx analysis, γ-H2AX<sup>low</sup> LMS showed higher mast cell infiltration than γ-H2AX<sup>high</sup> LMS (p = 0.038). In conclusion, H2AX mRNA and γ-H2AX protein expression are associated with distinct biological behavior, differences in the immune cell environment, and might serve as useful prognostic biomarkers in LMS.
Authors
- Nora Wuerdemann
- Peter Mallmann
- Reinhard Büttner (ORCID: https://orcid.org/0000-0001-8806-4786)
- Peer Eysel (ORCID: https://orcid.org/0000-0002-9929-3370)
- Lars Mortimer Schiffmann (ORCID: https://orcid.org/0000-0002-2320-5004)
- Lena Hieggelke (ORCID: https://orcid.org/0000-0002-1831-0387)
- Su Ir Lyu (ORCID: https://orcid.org/0009-0002-4125-6048)
- Alexander Quaas (ORCID: https://orcid.org/0000-0002-3537-6011)
- Christiane J. Bruns (ORCID: https://orcid.org/0000-0001-6590-8181)
- Sebastian G. Walter (ORCID: https://orcid.org/0000-0002-6203-8616)
- Anne M. Schultheis
- Roland T. Ullrich
- Karl Knipper (ORCID: https://orcid.org/0009-0008-7133-3538)
- Adrian Georg Simon (ORCID: https://orcid.org/0000-0002-2709-863X)
- David Stahl
Institutions
- University of Freiburg (DE)
- University of Cologne (DE)
- Düsseldorf University Hospital (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- International Journal of Cancer
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1002/ijc.35310
- Citations
- 3
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26